Comparative Pharmacology
Head-to-head clinical analysis: DIAZOXIDE versus HYLOREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAZOXIDE versus HYLOREL.
DIAZOXIDE vs HYLOREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diazoxide is a potassium channel activator that opens ATP-sensitive potassium channels in pancreatic beta cells, inhibiting insulin secretion. It also causes peripheral vasodilation by activating potassium channels in vascular smooth muscle.
Selective alpha-1 adrenergic receptor antagonist; inhibits sympathetic vasoconstriction, reducing peripheral vascular resistance and blood pressure.
Hypertension: 1-3 mg/kg IV bolus, up to 150 mg, repeated every 5-15 minutes to achieve desired blood pressure. Hyperinsulinemic hypoglycemia: 3-8 mg/kg/day PO divided every 8-12 hours.
10 mg orally twice daily, titrated to 20-40 mg twice daily based on blood pressure response.
None Documented
None Documented
Clinical Note
moderateDiazoxide + Torasemide
"Diazoxide may increase the hypotensive activities of Torasemide."
Clinical Note
moderateDiazoxide + Travoprost
"Diazoxide may increase the hypotensive activities of Travoprost."
Clinical Note
moderateDiazoxide + Unoprostone
"Diazoxide may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateDiazoxide + Epoprostenol
"Diazoxide may increase the hypotensive activities of Epoprostenol."
Terminal half-life: 20-36 hours (adults), 9-24 hours (children). Context: shorter after IV bolus due to redistribution; prolonged in renal impairment.
Approximately 12-15 hours; clinically, steady-state achieved in 2-3 days.
Renal: ~50% unchanged; minor biliary/fecal excretion.
Primarily renal (50-60% unchanged) and biliary/fecal (40-50%).
Category C
Category C
Antihypertensive Agent
Antihypertensive Agent